|
Video: What is a Stock Split?
|
|
Dianthus Therapeutics is a biotechnology company focused on improving stem cell transplantation. Co.'s MGTA-117 product candidate was designed as an antibody drug conjugate, or ADC, designed to deplete CD117-expressing stem cells in the bone marrow in order to make room for subsequently transplanted stem cells or ex vivo gene therapy products. Co.'s second targeted conditioning product candidate, MGTA-145, is an ADC designed to selectively target and deplete both stem cells and immune cells, and it is intended to replace the use of chemotherapy-based conditioning prior to stem cell transplant in patients with blood cancers and autoimmune diseases. According to our DNTH split history records, Dianthus Therapeutics has had 1 split. | |
|
Dianthus Therapeutics (DNTH) has 1 split in our DNTH split history database. The split for DNTH took place on September 12, 2023. This was a 1 for 16 reverse split, meaning for each 16 shares of DNTH owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 62.5 share position following the split.
When a company such as Dianthus Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DNTH split history from start to finish, an original position size of 1000 shares would have turned into 62.5 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Dianthus Therapeutics shares, starting with a $10,000 purchase of DNTH, presented on a split-history-adjusted basis factoring in the complete DNTH split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/22/2018 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$232.00 |
|
End price/share: |
$21.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-90.73% |
|
Average Annual Total Return: |
-33.41% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$926.97 |
|
Years: |
5.85 |
|
|
|
Date |
Ratio |
09/12/2023 | 1 for 16 |
|
|